Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
The Cleveland Clinic Identifier:
First received: December 20, 2005
Last updated: February 12, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2011
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)